Advancing Patient Care in Hypertrophic Cardiomyopathy: Key Insights from HFA 2024
Published: 22 May 2024
-
Views:
5180
-
Likes:
7
-
Views:
5180
-
Likes:
7
Overview
Recorded during HFA 2024, Dr Caroline Coats, Glasgow University, UK, and Dr Ahmad Masri, Oregon Health and Science University, US, collaborate to explore the pivotal advancements in managing hypertrophic cardiomyopathy unveiled at the conference.
This programme is thoughtfully divided into four chapters, facilitating a smooth journey through the latest HCM trial data, including a comprehensive analysis of the SEQUOIA trial results; the dynamic evolution of HCM management with forthcoming updates to practice guidelines and expert strategies for seamlessly integrating these evidence-based innovations into clinical practice.
Join Dr Coats and Dr Masri as they navigate the forefront of HCM management, offering invaluable insights and actionable strategies to elevate patient care.
Learning Objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
Target Audience
- Cardiologists
- Heart Failure Specialty Physicians
- Associated Nurses
- Nurse Practitioners
- Trainees
More from this programme
Part 1
Part 1
Part 2
Part 2
Part 3
Part 3
| 1 session | |
| Guidelines Updates | Watch now |
Part 4
Part 4
| 1 session | |
| Transition to Clinical Practice | Watch now |
Faculty Biographies
Ahmad Masri
Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.
He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.
Caroline Coats
Honorary Clinical Senior Lecturer
Dr Caroline Coats is an Honorary Clinical Senior Lecturer at the University of Glasgow, Glasgow, UK.
Dr Coats leads the West of Scotland Inherited Cardiac Conditions Service. She was awarded a Career Researcher Fellowship from the Chief Scientific Office and serves as Principal Investigator for several global clinical trials.
Comments